Department of Orthopaedic Surgery, Orthopaedic Trauma Service, University of Virginia School of Medicine, PO Box 800159, Charlottesville, VA 22908, USA.
Clin Orthop Relat Res. 2011 Sep;469(9):2665-9. doi: 10.1007/s11999-010-1738-1. Epub 2010 Dec 16.
Osteonecrosis (ON) of the femoral head is a devastating disease affecting young patients at their most productive age, causing major socioeconomic burdens. ON is associated with various etiologic factors, and the pathogenesis of the disease is unknown. Most investigators believe the disease is the result of secondary microvascular compromise with subsequent bone and marrow cell death and defective bone repair.
QUESTIONS/HYPOTHESES: We hypothesize that local delivery of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-6 (BMP-6), which induces angiogenesis and osteogenesis respectively, will reverse the disease process and provide a treatment for precollapse ON.
We will use genetically engineered bone marrow stem cells, carrying VEGF and BMP-6 genes, to enhance angiogenesis and osteogenesis in necrotic bone of an animal model, by local delivery of growth factor in addition to the bone-forming property of the stem cells. The participation, localization, and fate of the stem cells in the repair process will be evaluated by tracing marker-gene product. Osteogenesis and angiogenesis will be assessed using high-resolution xray CT and immunohistomorphometry quantitatively. Mechanical properties of the repair tissue will be determined using an indentation test of the femoral head.
We envision that a deliverable or injectable bone graft substitute containing engineered stem cells and therapeutic growth factors will be developed through this proposed study and will provide a much needed treatment for ON.
股骨头坏死(ON)是一种破坏性疾病,影响处于生产力高峰期的年轻患者,给社会经济带来重大负担。ON 与多种病因因素有关,其发病机制尚不清楚。大多数研究人员认为,该疾病是继发于微血管损伤,导致骨和骨髓细胞死亡和骨修复缺陷。
问题/假设:我们假设局部递送血管内皮生长因子(VEGF)和骨形态发生蛋白-6(BMP-6),分别诱导血管生成和成骨,将逆转疾病进程并为塌陷前 ON 提供治疗。
我们将使用携带 VEGF 和 BMP-6 基因的基因工程骨髓干细胞,通过局部递送生长因子来增强动物模型中坏死骨的血管生成和成骨作用,此外还利用干细胞的成骨特性。通过追踪标记基因产物来评估干细胞在修复过程中的参与、定位和命运。通过高分辨率 X 射线 CT 和免疫组织形态计量学定量评估成骨和血管生成。使用股骨头压痕试验确定修复组织的力学性能。
我们设想通过这项拟议研究,将开发出一种可输送或可注射的含工程化干细胞和治疗性生长因子的骨移植替代物,为 ON 提供急需的治疗。